Shire delivers strong revenue growth and cash generation

Shire delivers strong revenue growth and cash generation

April 30, 2015

Continued advancement toward goal of becoming a leading global biotechnology company

Shire (LSE: SHP, NASDAQ: SHPG) announces unaudited results for the three months to March 31, 2015.

Financial HighlightsQ1 2015Growth(1) CER(2)
Product sales$1,423 million+9%+13%
Total revenues$1,488 million+11%+15%
Non GAAP operating income$683 million+16%+19%
US GAAP operating income from continuing operations$475 million+55% 
Non GAAP EBITDA margin (excluding royalties & other revenues)(3)46%+1pps(4) 
US GAAP net income margin(5)28%+11pps 
Non GAAP diluted earnings per ADS$2.84+20%+24%
US GAAP diluted earnings per ADS$2.08+77% 
Non GAAP cash generation$516 million+56% 
Non GAAP free cash flow$542 million+135% 
US GAAP net cash provided by operating activities$562 million+128% 

(1) Percentages compare to equivalent 2014 period.
(2) On a Constant Exchange Rate (“CER”) basis, which is a Non GAAP measure.
(3) Non GAAP earnings before interest, tax, depreciation and amortization (“EBITDA”) as a percentage of product sales, excluding royalties and other revenues.
(4) Percentage point change (“PPS”).
(5) US GAAP net income as a percentage of total revenues.

The Non GAAP financial measures included within this release are explained on page 25, and are reconciled to the most directly comparable financial measures prepared in accordance with US GAAP on pages 19 - 22 of the full release.


  • Strong product sales growth of 9% (13% on a CER basis) to $1.4 billion, driven by performance of VYVANSE®, CINRYZE®, FIRAZYR® and LIALDA®/MEZAVANT®.
  • Non GAAP earnings per ADS up 20% (up 24% on a CER basis).
  • Acquisition of NPS Pharmaceuticals, Inc. (“NPS”) completed and integration progressing according to plan.
  • Commercial portfolio strengthened through the addition of GATTEX®/REVESTIVE® and NATPARA® from NPS and the launch of VYVANSE for Binge Eating Disorder in adults.
  • Pipeline progressed, with the most significant developments being Priority Review for lifitegrast and agreement with the FDA on the regulatory path for SHP465. Shire now has its broadest and deepest pipeline in its history.

Flemming Ornskov, M.D., Shire’s Chief Executive Officer, commented:

During the first quarter, Shire continued to exemplify the characteristics of a leading biotechnology company, delivering strong revenue growth and cash generation, while materially advancing our innovative pipeline and boosting our future growth profile through the acquisition of NPS. Our continued financial performance driven by the strength of our commercial operations, focus on efficiency, and breadth of our innovative pipeline are indicators of our bright future. We remain confident in delivering Non GAAP diluted earnings per ADS growth in the mid-single digits in 2015 (high single digit growth on a CER basis).

For further information please contact:

Investor Relations

Sarah Elton-Farr
[email protected]
+44 1256 894157


Michele Galen
[email protected]
+1 781 482 1867

Brooke Clarke
[email protected]
+44 1256 894 829


Dial in details for the live conference call for investors at 14:00 BST / 09:00 EDT on April 30, 2015:

UK dial in: 0808 237 0030 or 0203 139 4830
US dial in: 1 866 928 7517 or 1 718 873 9077
International Access Numbers: Click here
Password/Conf ID: 54094197#
Live Webcast: Click here


The quarterly earnings presentation will be available today at 13:00 BST / 08:00 EDT on: Investors section
Shire's IR Briefcase in the iTunes Store


Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

Click here for the PDF version of this press release.